National Chung Cheng University, Republic of China
Yung-Chih Kuo is a professor at the Department of Department of Chemical Engineering, National Chung Cheng University. His research interests are focused on biomaterials, drug delivery system, tissue engineering, blood–brain barrier, stem cell differentiation, nerve regeneration, cancer therapy, Alzheimer’s disease treatment, biophysics, and colloid and interface science. In these fi elds, he has authored or coauthored over 100 SCI journal papers. He won Young Scholar Award in 2003 and Outstanding Research Award in 2010-13. He is also an associate editor of J. Taiwan Inst. Chem. Eng. (Impact factor 2.637) and an editorial board member in 11 international journals.
Lactoferrin (Lf) and folic acid (FA) were crosslinked on poly(lactide-co-glycolide) (PLGA) nanoparticles (NPs) for transporting etoposide across the blood–brain barrier (BBB) and treating human brain malignant glioblastoma. Lf- and FA-graft ed PLGA NPs (Lf/FA/PLGA NPs) were employed to permeate the monolayer of human brain-microvascular endothelial cells (HBMECs) regulated by human astrocytes and to inhibit the multiplication of U87MG cells. Lf/FA/PLGA NPs showed a satisfactory entrapment effi ciency of etoposide and characteristics of sustained drug release. When compared with PLGA NPs, the permeability coeffi cient for etoposide across the BBB using Lf/FA/PLGA NPs increased about twofold. Th e antiproliferative effi cacy against the growth of U87MG cells was in the following order: Lf/FA/PLGA NPs > FA/PLGA NPs > PLGA NPs > free etoposide solution. In addition, the targeting ability of Lf/FA/PLGA NPs was evidenced by immunostaining of Lf receptor on HBMECs and folate receptor on U87MG cells during endocytosis. Lf/FA/PLGA NPs with loaded etoposide can be a promising anticancer pharmacotherapy to enhance the delivery of etoposide to malignant brain tumors for preclinical trials.